S&P 5007,575.39▲0.4% Nasdaq26,281.61▲0.3% Dow52,637.01▲0.3% Russell 2K2,977.81▼0.5% 10-Yr4.57%+3bp VIX15.03−0.81 WTI$71.51▼0.8% Gold$4,128.90▼0.0% EUR/USD1.142▼0.0% BTC$64,410▲0.4% Nikkei67,744▲1.4%
At close · Fri, Jul 10, 2026
Daily Market Updates.

US Markets

Home›US Markets›Equities›Vivani Medical develops semaglutide implant for weight…

Vivani Medical develops semaglutide implant for weight loss

The implant uses semaglutide, the active ingredient in Novo Nordisk’s Wegovy and Ozempic, which are already used for obesity and diabetes treatment.

Reported · Written up by our desk · Equities

CNBC Markets reports Vivani Medical is developing a tiny implant intended to help patients maintain weight loss.

The company’s approach centers on delivering semaglutide, the active ingredient in Novo Nordisk’s obesity injection Wegovy and diabetes drug Ozempic.

The report frames the project as a new way to sustain results for patients using established GLP-1 based therapies.

← Newer storyAmazon layoffs spotlight worker strain in a saturated job market

More like this

US MarketsBerkshire Hathaway B shares trail the S&P 500 in 2026
US MarketsAmazon layoffs spotlight worker strain in a saturated job market
US MarketsBrother claimed Social Security at 70, died after one payment
US MarketsApple sues OpenAI alleging theft of confidential information
US MarketsSouth Korean memory chip maker’s U.S. debut lifts stocks

Sources

CNBC MarketsA tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.